- Home
- MRNO vs REPL Comparison
MRNO vs REPL Comparison
Compare MRNO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNO
- REPL
- Stock Information
- Founded
- MRNO 2021
- REPL 2015
- Country
- MRNO United Kingdom
- REPL United States
- Employees
- MRNO N/A
- REPL N/A
- Industry
- MRNO
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- MRNO
- REPL Health Care
- Exchange
- MRNO NYSE
- REPL Nasdaq
- Market Cap
- MRNO 794.8M
- REPL 780.3M
- IPO Year
- MRNO N/A
- REPL 2018
- Fundamental
- Price
- MRNO $11.05
- REPL $10.14
- Analyst Decision
- MRNO
- REPL Strong Buy
- Analyst Count
- MRNO 0
- REPL 6
- Target Price
- MRNO N/A
- REPL $17.50
- AVG Volume (30 Days)
- MRNO 7.3K
- REPL 794.9K
- Earning Date
- MRNO 02-21-2025
- REPL 02-06-2025
- Dividend Yield
- MRNO N/A
- REPL N/A
- EPS Growth
- MRNO N/A
- REPL N/A
- EPS
- MRNO N/A
- REPL N/A
- Revenue
- MRNO $27,954,510.00
- REPL N/A
- Revenue This Year
- MRNO N/A
- REPL N/A
- Revenue Next Year
- MRNO N/A
- REPL $300.41
- P/E Ratio
- MRNO N/A
- REPL N/A
- Revenue Growth
- MRNO 211.17
- REPL N/A
- 52 Week Low
- MRNO $3.60
- REPL $4.92
- 52 Week High
- MRNO $38.00
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- MRNO 57.81
- REPL 32.06
- Support Level
- MRNO $10.60
- REPL $10.00
- Resistance Level
- MRNO $12.15
- REPL $11.20
- Average True Range (ATR)
- MRNO 0.81
- REPL 0.84
- MACD
- MRNO 0.04
- REPL -0.20
- Stochastic Oscillator
- MRNO 54.91
- REPL 3.93
About MRNO MURANO GLOBAL INVESTMENTS LIMITED
Murano Global Investments PLC is a real estate company that owns, develops, and invests in hotel, resort, and commercial properties throughout Mexico. Its portfolio includes the Andaz and Mondrian Hotels in Mexico City and Vivid Hotel Grand Island. The revenues are derived from the products and services provided to our customers such as Room rentals, Food and beverage, Private events, Spa services, and Other services.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.